Loading clinical trials...
Loading clinical trials...
Single-dose, Open-label, 2 Periods, 2 Sequences, Randomized Crossover Bioequivalence Study of Aviga 50 mg Capsules (JLLC NATIVITA, Belarus) and Sutent 50 mg Capsules (Pfizer Italia S.R.L.) in Healthy Volunteers Under Fasting Conditions
Conditions
Interventions
Aviga, capsules 50 mg / Sutent®, capsules 50 mg
Sutent®, capsules 50 mg / Aviga, capsules 50 mg
Locations
1
Belarus
National Anti-Doping Laboratory
Lyasny, Minsk Oblast, Belarus
Start Date
January 21, 2022
Primary Completion Date
March 3, 2022
Completion Date
May 3, 2022
Last Updated
February 1, 2022
NCT07345130
NCT06969963
NCT06924190
NCT06830954
NCT06758531
NCT06600282
Lead Sponsor
JLLC NatiVita
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions